Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

Abstract: The invention describes anti-cancer therapies comprising using an LRP5 antagonist in combination with an anti-PD1 antibody, each as described herein.

Abstract: The present invention relates to clinically proven subcutaneous pharmaceutical compositions comprising anti-CD38 antibodies and methods of their uses in combination with lenalidomide and dexamethasone.

Abstract: Bispecific binding proteins that bind IL-1? or IL-1R and a checkpoint protein are provided, together with methods of making the proteins. The checkpoint protein may be PD-1 or PD-L1. The binding proteins may have immunoglobulin-like structures that contain human Fab or scFv domains. A novel bispecific antibody format is provided. Methods of making the binding proteins are provided, together with pharmaceutical compositions containing the proteins. The binding proteins and pharmaceutical compositions may be used for treating or preventing diseases such as cancer.

Abstract: Provided herein are the use of FGFR3 inhibitors and taxanes to treat solid and hematologic cancers, as well as compositions and kits comprising an FGFR3 inhibitor and a taxane.

Abstract: The present invention provides Wnt pathway agonists and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of diseases.

Abstract: The description concerns humanized antibodies directed against the extracellular domain of the alpha chain of the receptor for interleukin-7 (IL-7), especially against the receptor for human IL-7 expressed on human cells (also designated human Th-7Ralpha or IL-7Ra or CD127) and which do not interfere with the IL-7 or TSLP signaling pathways. The antibodies described do not have an antagonistic effect on the IL-7 receptor, but may still present cytotoxic activity against CD127 positive cells. In a particular embodiment, the antibody does not have an agonist effect on the IL-7 receptor.

Abstract: The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain specific for TSLPR, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of a proliferative disorder, e.g., cancer, in a mammal and methods of treating or preventing a proliferative disorder, e.g., cancer, in a mammal are also disclosed.

Abstract: The present disclosure relates to antibodies directed to CD25 and uses of such antibodies, for example to suppress organ transplant rejection or to treat multiple sclerosis.

Abstract: The present invention provides anti-CD115 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic and diagnostic methods for the treatment of cancer, autoimmune, and other diseases.

Abstract: Provided herein are methods and compositions for treating a subject suffering from an enzyme deficiency in the central nervous system (CNS). The bifunctional fusion antibodies provided herein comprise an antibody to an endogenous blood brain barrier (BBB) receptor and an enzyme deficient in mucopolysaccharidosis III (MPS-III). The fusion antibodies provided herein comprise N-sulfoglucosamine sulfohydrolase (SGSH), alpha-N-acetylgulcosaminidase (NAGLU), heparin-alpha-glucosaminide N-acetyltransferase (HGSNAT), or N-acetylglucosamine-6-sulfatase (GNS). The methods of treating an enzyme deficiency in the CNS comprise systemic administration of a fusion antibody provided herein.

Abstract: The present disclosure relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering combinations of antibodies, or antigen-binding fragments thereof, that bind to CD137, and tumor antigen-targeting antibodies.

Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.

Abstract: Provided herein, inter alia, are compositions and methods of using the same for detecting complement activation.

Abstract: The present invention relates to clinically proven subcutaneous pharmaceutical compositions comprising anti-CD38 antibodies and methods of their uses in combination with pomalidomide and dexamethasone.

Abstract: The present invention relates to clinically proven subcutaneous pharmaceutical compositions comprising anti-CD38 antibodies and their uses.

Abstract: Disclosed herein are anti-lymphocyte antigen 6 complex, locus H (LY6H) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

Abstract: Provided is a novel anti-Glypican-1 antibody and a method for using the same. Provided is an anti-Glypican-1 antibody having an intracellular invasion activity which has never been observed in conventional anti-Glypican-1 antibodies. By taking advantage of the intracellular invasion activity of the antibody according to the present invention, the present invention is usable for various therapeutic purposes beyond the scope of the conventional assumption. Also provided is a composition for preventing or treating Glypican-1 positive cancer, said composition comprising a complex of a substance capable of binding to Glypican-1 (for example, an anti-Glypican-1 antibody) with a drug having a cytotoxic activity.

Abstract: Chimeric transmembrane immunoreceptors (CAR) targeted to PSCA are described.

Abstract: The present disclosure relates to reversal agents, which specifically bind to anti-Factor XI and/or anti-Factor XIa antibodies, and reverse one or more anticoagulant effects of the anti-Factor XI and/or anti-Factor XIa antibodies, as well as to methods of use thereof, such as methods for reversing anticoagulant effects of such anti-Factor XI and/or anti-Factor XIa antibodies, and to related methods for managing bleeding or bleeding risks.

Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.

Abstract: The present invention further relates to specific humanised monoclonal antibodies inhibiting ADAMTS13 function. The present invention relates to methods of treatment by human ADAMTS13 inhibition in circulatory assist device induced haemorrhagic complication such as a bleeding disorder, in particular, bleeding after left ventricular assist device (LVAD) implantation.

Abstract: The instant disclosure provides antibody fragments (e.g., Fab and F(ab?)2) having reduced or no reactivity towards pre-existing anti-hinge antibodies (AHA) and compositions comprising such antibody fragments, as well as methods of making and using such antibody fragments and compositions.

Abstract: The present disclosure relates to chimeric engulfment receptor molecules, host cells modified to include the phagocytic engulfment molecules, and methods of making and using such receptor molecules and modified cells.

Abstract: Compositions, methods, assays, and kits providing or incorporating derivatives of mitragynine, particularly as haptens and immunogens.

Abstract: The present invention relates to transgenic mammals that express canine-based immunoglobulins, including transgenic rodents that express canine-based immunoglobulins for the development of canine therapeutic antibodies.

Abstract: VISTA antigen-binding molecules are disclosed. Also disclosed are nucleic acids and expression vectors encoding, compositions comprising, and methods using, the VISTA antigen-binding molecules.

Abstract: The invention relates to bivalent bispecific monoclonal antibodies (bbmAb) or variants thereof, and methods of manufacturing such antibodies by co-expressing modified Fc-mutated derivatives of two different monoclonal antibodies in mammalian cell lines.

Abstract: A modified cellulose, method for preparing the same and use thereof. The structural formulas of the modified cellulose are shown in Formula (I), Formula (II) or Formula (III): wherein, n is 2-7; the modified cellulose is obtained by substitution. The cellulose is substituted and modified with long-chain compounds containing amino terminal groups, so that the modified cellulose has space formed by long chains and amino terminal groups, which can be used as a matrix in solid-phase peptide synthesis (SPOT), to increase reaction activity and reaction space, reduce the difficulty of peptide synthesis, realize SPOT well, be suitable for synthesis in an automatic synthesizer, have high yield, and have low cost.

Abstract: The invention relates to a method of producing a heat-modified starch comprising the steps of: (i) preparing a starch milk containing between 30 and 40% by weight, preferably between 35 and 37% by weight, solid matter, (ii) adding a powdery alkaline agent such as to obtain a final conductivity of between 0.7 and 2.5 mS/cm, (iii) ensuring a contact time of between 0.5 and 5 hours, (iv) filtering and drying the starch milk, (v) and heating the dried starch to bring it to a temperature of more than 180° C. for a dwell time of between 8 and 50 minutes, preferably between 10 and 40 minutes, even more preferably between 12 and 35 minutes.

Abstract: The present invention relates to a process for the hydrogenation of the carbon-carbon double bonds in nitrile butadiene rubber which is present in latex form, this means as a suspension of nitrile butadiene rubber particles in an aqueous medium, using a hydrogenation catalyst in the presence of an emulsifier.

Abstract: A modified liquid diene rubber (A) has a functional group (a) derived from an acid anhydride, and satisfies all the requirements (I) to (III) below: (I) The functional group equivalent weight of the functional groups (a) is in the range of 400 to 3,500 g/eq. (II) The polystyrene-equivalent number average molecular weight (Mn) measured by gel permeation chromatography (GPC) is in the range of 5,000 to 20,000. (III) The melt viscosity at 38° C. is not less than 3 Pa·s and X (K) is not less than 6100 K wherein X is the slope of a linear line passing through two points in a graph in which the two points are values of melt viscosity ? (Pa·s) at 38° C. and 60° C. measured with a Brookfield viscometer which are plotted as Ln[?/(Pa·s)] on ordinate versus 1/T (K?1) on abscissa (with the proviso that T is temperature (K)).

Abstract: Process for producing aqueous polyacrylamide solutions by polymerizing an aqueous solution comprising at least acrylamide thereby obtaining an aqueous polyacrylamide gel and dissolving said aqueous polyacrylamide gel in water, wherein the manufacturing steps are allocated to two different locations A and B and the process comprises the step of transporting an aqueous monomer premix from a location A to a location B. Modular, relocatable plant for manufacturing aqueous polyacrylamide solutions wherein the units of the plant are located at two different locations A and B.

Abstract: This invention relates to transition metal complexes represented by the formula: catalyst systems comprising the complexes, and polymerization methods for olefinic monomers using the catalyst systems. In said formula, M is a transition metal; E is NR2, CR3R4, O, S, or SiR5R6; Q is optional substitution; p is an integer ranging from 0 to 3; L is an optional neutral ligand; m is an integer ranging from 0 to 3; X is an anionic leaving group; n is 1 or 2, with m+n being 4 or less; J is a linker group contributing two or three atoms that are located within a first chelate ring; R1 and R1? are independently a hydrocarbyl group or a trihydrocarbylsilyl group; R2 is a hydrocarbyl group; R3 and R4 are independently H, a hydrocarbyl group, or a trihydrocarbylsilyl group; and R5 and R5 are independently a hydrocarbyl group.

Abstract: The present disclosure provides base stocks and or diesel fuel, and processes for producing such base stocks and or diesel fuel by polymerizing alpha-olefins and internal olefins. The present disclosure further provides polyolefin products useful as base stocks and or diesel fuel. In at least one embodiment, a process includes: i) introducing, neat or in the presence of a solvent, a feed comprising a branched C5-C30 internal olefin, with a catalyst compound comprising a group 8, 9, 10, or 11 transition metal and at least one heteroatom and ii) obtaining a C6-C100 polyolefin product having one olefin, a methylene content of from about 1 wt % to about 98 wt %, and or a methyl content of from about 1 wt % to about 75 wt %. The feed may further include a linear C4-C30 internal olefin, a C2-C30 alpha-olefin, or a mixture thereof.

Abstract: Provided is a particle drying method capable of sufficiently removing the volatile component and down-regulating the increase of the viscosity of the particles after the removal of the volatile component. There is provided a method for producing heterophasic propylene polymerization material particles, the method including: (1) performing monomer polymerization in the presence of a catalyst including a solid catalyst component so as to obtain a component I; (2) performing monomer polymerization in the presence of the component I so as to obtain the component II, so that particles including a volatile component are produced; and (3) causing the particles to contact with an inert gas-containing stream so as to remove the volatile component from the particles.

Abstract: The disclosure describes the preparation and use of reactive carbonates containing a metal carbonate bound to a reactive compound, wherein the reactive compound comprises a mineral binding group and a polymer reactive group connected together by a linking group. Such reactive carbonates are useful as reagents in processes for making mineral-bound elastomeric materials, and in methods for reducing cavitation in elastomer materials.

Abstract: A high molecular weight polyethylene polymer is formulated so that the polymer is capable of being injection molded. The polyethylene polymer has a Viscosity Number of greater than about 400 ml/g and has a melt flow rate of greater than about 0.9 g/10 min. The polyethylene polymer is of high purity and is particularly well suited for producing medical products.

Abstract: A curable composition can comprise a polymerizable compound and a dual-functional photoinitiator, wherein the dual-functional photoinitiator includes a photo-active group and at least one functional group capable of forming a covalent bond with the polymerizable compound during curing of the curable composition. The curable composition can have a viscosity of not greater than 10 mP·s at a temperature of 23° C. and an increased glass transition temperature after curing in comparison to a corresponding curable composition including a mono-functional photoinitiator.

Abstract: Crosslinkable polymeric materials, crosslinked polymeric materials, articles containing the crosslinkable polymeric materials or crosslinked polymeric materials, and methods of making the articles and various compositions are provided. More particularly, the crosslinkable composition contains a) a first polymeric material, which has terminal dithiocarbamate or dithiocarbonate groups, b) a crosslinking composition containing a chlorinated triazine crosslinking agent and/or a crosslinking monomer having two or more ethylenically unsaturated groups, and c) a thixotropic agent containing metal oxide particles. The crosslinkable composition may be printable or dispensed. In some embodiments, the crosslinked composition is a pressure-sensitive adhesive.

Abstract: The present application provides a catalyst component for alkene polymerization. The catalyst component contains: (a) a group 4 transition metal or rare earth metal, (b) a rigid non-cyclopentadienyl ligand with a tricyclic backbone composed of three ortho-fused 6-membered rings in a linear arrangement (as is the case in xanthene), with or without additional fused rings; the tricyclic backbone contains at least one donor atom within the central ring (as is the case for xanthene, oxanthrene, or acridan); furthermore, donor atoms/groups or aryl rings are attached directly (i.e. via the donor atom in the case of donor groups) to both of the bondable carbon atoms adjacent to at least one of the donor atoms within the central ring (e.g.

Abstract: The present invention provides an organometal catalyst having a cationic metal complex and a borate-based bulky anion, where the metal is one or more selected from the group consisting of metals in group 13, a method for preparing the same, and a method for preparing an oligomer or a polymer using the same.

Abstract: The present invention provides a polyolefin composition, said composition comprising a terpolymer comprising a cross-linkable polyolefin comprising hydrolysable silane groups and a polar comonomer, the polyolefin composition further comprising a cross-linking catalyst and a silicon containing compound. The polar comonomer Is present in an amount of 5-35 wt %.

Abstract: A composition used to form an insulating part for insulating metal wiring in the electric and electronic devices having the metal wiring, and including a resin (A) having a group represented by formula (a1). The group represented by formula (a1) is bonded to a carbon atom in an aliphatic hydrocarbon group or an aromatic group of a main chain and/or a side chain of resin (A), and the carbon atom is located in a position other than a terminal of main chain of resin (A).

Abstract: Higher throughput in aqueous addition polymerization is made possible by use of an external shell and tube heat exchanger operated in reverse mode, with coolant flowing through the tubes and polymerization mixture flowing through the shell around the tubes.

Abstract: It is to provide an antistatic material that can maintain a high degree of electrostatic charge quenching performance over a long period without using an internally kneaded type antistatic agent, a method for manufacturing the same, and a method for preventing electrification using the same. An antistatic material of the present invention is that comprising an acrylic resin which is obtained by copolymerization of an acrylic monomer as an essential component including 70% by weight or more of methyl methacrylate and have in a main chain a structural unit of the following formula (1) having a side chain including a donor-acceptor molecular compound type atomic group consisting of non-ionic pair, in a proportion of 0.5 to 5% by weight based on a whole resin.

Abstract: A polymeric composition including a copolymer comprising a first monomer having a high carbon to oxygen ratio of from about 3 to about 8; a second monomer comprising two or more vinyl groups, wherein the second monomer is present in the copolymer in an amount of from greater than about 8 percent by weight to about 60 percent by weight, based on the weight of the copolymer; and, optionally, a third monomer comprising an amine, wherein the third monomer, if present, is present in an amount of from about 0.5 percent by weight to about 5 percent by weight, based on the weight of the copolymer. A toner including the copolymer as a toner surface additive. An emulsion aggregation toner process including the copolymer as a toner surface additive.

Abstract: The present teachings relate to various embodiments of a curable ink composition, which once printed and cured form polymeric films on a substrate such as, but not limited by, an OLED device substrate. Various embodiments of the curable ink compositions comprise di(meth)acrylate monomers, as well as multifunctional crosslinking agents and curing kinetics control additives.

Abstract: A composition including a three-dimensional polymeric printing powder; an organic polymeric additive on at least a portion of an external surface of the three-dimensional polymeric printing powder; wherein the organic polymeric additive is optionally cross-linked; and optionally, an inorganic additive on at least a portion of an external surface of the three-dimensional polymeric printing powder. A process for preparing a three-dimensional polymeric printing powder having an organic polymeric additive disposed thereon. A process for employing the three-dimensional polymeric printing powder including selective laser sintering.

Abstract: The present invention provides a graft copolymer comprising: (a) a hydrophobic functional polymeric backbone, wherein the backbone comprises (i) an acrylate polymer, an alkylacrylate polymer, or both an acrylate polymer and an alkylacrylate polymer, wherein the backbone has an average molecular weight (M) of from about 3,000 to about 100,000; and (b) a plurality of hydrophilic polymeric side chains attached to the hydrophobic functional polymeric backbone, wherein the hydrophilic polymeric side chains comprise a polymerization product of at least one polymerizable unsaturated monomer and a polymerizable amine-containing unsaturated monomer.